UPTEMPO
Live / Applied — Third extension granted (statement of use) (as of 10 Nov 2025)
What this means for you
Not registered yet, but its 04 May 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97921045
- Mark type
- Stylized text
- Filed
- 04 May 2023
- Published for opposition
- 23 Jan 2024
- Attorney of record
- Vanessa A. Ignacio, Esq.
Goods and services
- Class 001 — Chemicals: Cells and cell lines for scientific, laboratory or medical research; Reagents for scientific or medical research use; Biological and biochemical preparations, namely, plasmids, RNA and proteins for scientific, medical research, or research use; Cell culture reagents for scientific and research use; Stem cells for research or scientific purposes; Biological preparations for use in cell cultures other than for medical or veterinary use; Engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, chimeric antigen receptor (CAR) T-cell preparations, T-cell preparations, tumor-infiltration lymphocyte (TIL) preparations, natural killer (NK) cell preparations, induced pluripotent stem cell (iPSC) preparations, mesenchymal stem cell (MSC) preparations, all for use in scientific research and analysis
- Class 005 — Pharmaceuticals: Cells and cell lines for medical or clinical use; Stem cells for medical or veterinary use; Engineered proteins for use in scientific research and analysis relating to genetic diseases, gene therapy, and cell therapy; biochemicals and biologics, namely, engineered nucleic acids, viral vectors, non-viral vectors, gene therapy vectors, gene editing vectors, DNA plasmids, genetically modified cells, engineered proteins for multiplexed gene editing, mRNA and recombinant adeno-associated virus (AAV) vectors for delivery of therapeutic DNA or mRNA sequences to cells, antibody preparations, chimeric antigen receptor (CAR) T-cell preparations, T-cell preparations, tumor-infiltration lymphocyte (TIL) preparations, natural killer (NK) cell preparations, induced pluripotent stem cell (iPSC) preparations, mesenchymal stem cell (MSC) preparations, all for clinical use, medical use, clinical laboratory use, and medical laboratory use; Pharmaceutical preparations in the nature of viral systems, gene therapy systems, and nucleic acid delivery systems comprised of viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells used to deliver modified genetic material into other cells for medical purposes
- Class 040 — Treatment of materials: Custom manufacture of cells and cell lines for use in viral vector production, and for diagnostic, medical and commercial applications in relation to cell and gene therapies
- Class 042 — Scientific and technological services: Pharmaceutical research and development; Gene therapy research; Cell therapy research; Scientific research
Owner
- CATALENT PHARMA SOLUTIONS, INC., Somerset, NJ, US
- CATALENT PHARMA SOLUTIONS, INC., Somerset, NJ, US
Prosecution history
- 21 Jan 2026 — TEAS STATEMENT OF USE RECEIVED
- 21 Jan 2026 — TEAS REQUEST TO DIVIDE RECEIVED
- 10 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Nov 2025 — SOU EXTENSION 3 GRANTED
- 10 Nov 2025 — SOU EXTENSION 3 FILED
- 10 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 15 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 14 May 2025 — SOU EXTENSION 2 GRANTED
- 14 May 2025 — SOU EXTENSION 2 FILED
- 14 May 2025 — SOU TEAS EXTENSION RECEIVED
- 27 Sept 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 27 Sept 2024 — SOU EXTENSION 1 GRANTED
- 27 Sept 2024 — SOU EXTENSION 1 FILED
- 27 Sept 2024 — SOU TEAS EXTENSION RECEIVED
- 14 May 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT